Olfactory Reference Syndrome (ORS)

Olfactory reference syndrome (ORS) is a body-focused psychiatric disorder characterized by persistent preoccupation (lasting at least 6 months) with the false belief that one is emitting an offensive body odor that others can detect, leading to clinically significant distress and impairment. Originally described in 1971 by Pryse-Phillips, ORS has been variably classified as a delusional disorder (somatic type), social anxiety variant, body dysmorphic disorder spectrum, and obsessive-compulsive spectrum disorder. ICD-11 (2022) recognizes ORS as a distinct entity within obsessive-compulsive and related disorders. DSM-5 includes ORS under 'other specified obsessive-compulsive and related disorders' but lacks distinct criteria. The reported prevalence is 0.5-2% in psychiatric populations and likely underdiagnosed in primary care due to embarrassment and social stigma.

Clinical features: persistent preoccupation with body odor (fecal odor most common 30-50%, then sweat/body odor 25-35%, halitosis/oral odor 20-30%, urine odor 10-15%, genital/menstrual odor 5-15%, semen odor in men, multiple odors in subset), false beliefs that others notice and react negatively to the odor (referential beliefs about coughing, sniffing, gestures, comments, looking away), repetitive checking behaviors (sniffing self, asking for reassurance from family — sometimes hundreds of times daily), excessive cleansing (showering 3-10+ times daily, repeated tooth brushing, mouthwash use, deodorant overuse), masking attempts (excessive perfume, gum, mints, change of clothing multiple times daily), social avoidance and isolation, occupational and educational impairment, dietary modifications to reduce perceived odor (avoiding garlic, onion, certain foods, fasting), excessive medical consultations (general practitioner, ENT, gastroenterology, dental seeking causes for non-existent odor). Insight varies: good insight (recognizes belief is unrealistic but cannot stop preoccupation), fair insight, poor insight, absent (delusional ORS — held with delusional intensity, no insight). Onset typically in adolescence or young adulthood (peak age of onset 15-25 years), male predominance (1.5:1), often after stressful event or perceived odor incident (one episode of being told they smelled by peer or family member can trigger lifelong syndrome).

ORS is associated with high psychiatric comorbidity: major depression (50-70%), anxiety disorders (40-60% — particularly social anxiety), suicidal ideation (30-50%), suicide attempts (5-30%), substance use disorders, body dysmorphic disorder, obsessive-compulsive disorder, schizophrenia spectrum (in delusional ORS). Diagnostic evaluation: detailed history (preoccupation, beliefs, behaviors, level of insight, distress, impairment), psychiatric examination (mental status, mood, anxiety, suicide risk, insight assessment), medical workup to rule out true causes of body odor (dermatological evaluation, sweat tests, halitosis evaluation, vaginal/genital exam, dental evaluation, GI evaluation for trimethylaminuria — fish odor syndrome), psychometric assessment (validated ORS scales, OCI-R, BDD-YBOCS modified). Treatment: selective serotonin reuptake inhibitors (SSRIs) at high doses similar to OCD treatment (sertraline 200-300 mg, fluoxetine 60-80 mg, paroxetine 60 mg, citalopram 40-60 mg) — primary pharmacotherapy with response in 60-80% over 8-12 weeks, augmentation with atypical antipsychotics (risperidone, aripiprazole) for delusional or treatment-resistant cases, particularly with poor insight. Cognitive-behavioral therapy (CBT) with exposure and response prevention — gradual exposure to social situations without performing safety/checking behaviors, cognitive restructuring of false beliefs, behavioral experiments to test reality of odor perception, support for distress tolerance. Treatment of comorbidities (depression, anxiety, suicidal ideation), avoidance of unnecessary medical interventions for non-existent odor, family education and involvement, support groups, long-term follow-up. Prognosis: chronic course with fluctuations common, but significant improvement with SSRI plus CBT in 60-70%, complete remission in 20-30%, with persistent residual symptoms in many. Trimethylaminuria (FMO3 mutations) — true metabolic cause of fish-like body odor — must be excluded with urinary trimethylamine testing in patients endorsing fishy odor.